O. V. Kudyasheva
Research Subjects
Research Interests
O. V. Kudyasheva has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander Dmitrievich Kulagin
Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
2 shared publications - Ivan Sergeevich Moiseev
Pavlov First Saint Petersburg State Medical University
2 shared publications - M. V. Chernous
RM Gorbacheva Research Institute, Pavlov University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022
2 shared publications - Olga Vladislavovna Pirogova
RM Gorbacheva Research Institute, Pavlov University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022
2 shared publications - A. A. Smirnova
Tver State Medical University
1 shared publication - A. M. Ananyin
Pavlov University
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Diagnostic Labyrinth of POEMS Syndrome: An Analysis of Real-World Clinical Practice
BACKGROUND. РOEMS syndrome is a rare multisystem syndrome associated with monoclonal proliferation of plasma cells or B-lymphocytes and based on cytokine-mediated pathogenetic mechanism. Despite the clear diagnostic criteria, timely verification of the diagnosis is challenging due to the extreme variability of clinical features. AIM. To study clinical and laboratory profile as well as diagnostic routes of patients with РOEMS syndrome. MATERIALS & METHODS. This retrospective observational study enrolled 40 patients with newly diagnosed РOEMS syndrome treated at two major centers for hematology in the period from 01.2016 to 09.2025. RESULTS. On the date of POEMS syndrome diagnosis, the median age of patients was 58 years (range 28–80 years), and median time from symptom manifestation to diagnosis was 23 months (range 1–146 months). On initial presentation at the Federal center, 30 % of patients were severely disabled and completely immobilized. All of them met two essential criteria: polyneuropathy and monoclonal gammopathy. In the vast majority of cases, polyneuropathy manifested itself in a sensory and motor form (87.5 %) with predominantly mixed axonal and demyelinating lesions (79.4 %). Paraprotein was identified in 97.5 % of patients, however in 30 % of them the pathologic clone of plasma cells was not detected by standard techniques. Other manifestations of POEMS syndrome include bone abnormalities (62.5 %), increased VEGF level (73 %), organomegaly (75 %), endocrinopathy (60 %), skin lesions (52.5 %), extravascular fluid overload (47.5 %), and thrombocytosis/polycythemia (45 %). Prior to diagnosis verification, on average, patients were examined by 3 (range 1–6) medical specialists, most often by a neurologist (62.5 %). At the diagnostic stage, chronic inflammatory demyelinating polyneuropathy (32.5 %) was widely and wrongly assumed. After examination by related specialists, 80 % of patients were referred to a hematologist. In 50 % of cases, lymphoproliferative diseases were identified, however, without verification of POEMS syndrome. In 20 % of patients, myeloproliferative neoplasia was wrongly diagnosed. CONCLUSION. For timely diagnosis of POEMS syndrome, medical specialists should raise awareness and alertness concerning its polymorphic clinical features and additionally strengthen interdisciplinary approaches.
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Open AccessDiagnostic Labyrinth of POEMS Syndrome: An Analysis of Real-World Clinical Practice
BACKGROUND. РOEMS syndrome is a rare multisystem syndrome associated with monoclonal proliferation of plasma cells or B-lymphocytes and based on cytokine-mediated pathogenetic mechanism. Despite the clear diagnostic criteria, timely verification of the diagnosis is challenging due to the extreme variability of clinical features. AIM. To study clinical and laboratory profile as well as diagnostic routes of patients with РOEMS syndrome. MATERIALS & METHODS. This retrospective observational study enrolled 40 patients with newly diagnosed РOEMS syndrome treated at two major centers for hematology in the period from 01.2016 to 09.2025. RESULTS. On the date of POEMS syndrome diagnosis, the median age of patients was 58 years (range 28–80 years), and median time from symptom manifestation to diagnosis was 23 months (range 1–146 months). On initial presentation at the Federal center, 30 % of patients were severely disabled and completely immobilized. All of them met two essential criteria: polyneuropathy and monoclonal gammopathy. In the vast majority of cases, polyneuropathy manifested itself in a sensory and motor form (87.5 %) with predominantly mixed axonal and demyelinating lesions (79.4 %). Paraprotein was identified in 97.5 % of patients, however in 30 % of them the pathologic clone of plasma cells was not detected by standard techniques. Other manifestations of POEMS syndrome include bone abnormalities (62.5 %), increased VEGF level (73 %), organomegaly (75 %), endocrinopathy (60 %), skin lesions (52.5 %), extravascular fluid overload (47.5 %), and thrombocytosis/polycythemia (45 %). Prior to diagnosis verification, on average, patients were examined by 3 (range 1–6) medical specialists, most often by a neurologist (62.5 %). At the diagnostic stage, chronic inflammatory demyelinating polyneuropathy (32.5 %) was widely and wrongly assumed. After examination by related specialists, 80 % of patients were referred to a hematologist. In 50 % of cases, lymphoproliferative diseases were identified, however, without verification of POEMS syndrome. In 20 % of patients, myeloproliferative neoplasia was wrongly diagnosed. CONCLUSION. For timely diagnosis of POEMS syndrome, medical specialists should raise awareness and alertness concerning its polymorphic clinical features and additionally strengthen interdisciplinary approaches.
- Open Access
- 1 July 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (3) , 237-245
Impact of Cardiac Disease on Prognosis in Patients with Systemic AL Amyloidosis
AIM. To assess the clinical features as well as the factors affecting prognosis and long-term treatment outcomes in systemic AL amyloidosis patients with cardiac involvement. MATERIALS & METHODS. The trial enrolled 123 systemic AL amyloidosis patients with cardiac involvement who were treated at the RM Gorbacheva Scientific Research Institute in 2004–2023. The patients were 34–85 years of age (median 61 years); there were 61 women (49.6 %) and 62 men (50.4 %). RESULTS. Cardiac disease grades 1, 2, 3a, and 3b were identified in 13.8 %, 50.4 %, 17.9 %, and 17.9 % of AL amyloidosis patients, respectively. Chronic cardiac failure (CCF) developed in 65.9 % (n = 81), and severe cardiac failure was detected in 25.4 % (n = 31) of patients. Most of them (90,2 %), despite CCF, preserved left ventricular ejection fraction (> 40 %) with the mean value of 59.6 % (range 33–78 %). The left ventricular stroke volume index (SVI) was below the normal values (< 41 mL/m2) in 92.7 % of patients. The mean SVI value was 26.1 mL/m2 (range 8.3–49.5 mL/m2). The lower SVI was associated with cardiac disease grades. This parameter appeared to be 30.9 mL/m2, 26.8 mL/m2, 24.8 mL/m2, and 21.4 mL/m2 in grades 1, 2, 3a, and 3b (p = 0.006), respectively. Total global strain (TGS) in the left ventricle myocardium was decreased (< 20 %) in 94.6 % of patients. The mean TGS value was 13.8 % (range 4.4–34.8 %). TGS was diminishing with increasing cardiac disease grade (grade 1 with 17.8 %, grade 2 with 14.6 %, grade 3a with 13.1 %, and grade 3b with 9.6 %) (p = 0.007). Atrial fibrillation was reported in 23 % of patients, supraventricular tachycardia was observed in 31.9 %, and supraventricular extrasystoles were registered in 39.7 %. Ventricular extrasystoles were found in 73.7 % of patients, and ventricular tachycardia was seen in 13.2 %. Sinoatrial block was reported in 6.6 % of patients, and atrioventricular block was identified in 19.8 %. Syncope occurred in 12.3 % of patients. An artificial cardiac pacemaker was implanted in 8 patients. The thromboembolism rate was 13 %: the myocardial infarction rate was 11.4 %, and the rate of acute cerebrovascular accidents was 5.7 %. Atrial clots were detected in 2 (1.6 %) patients. The cumulative incidence of hematologic response for 2 years was 57 % and did not depend on cardiac disease grade, the 2-year rate of cardiac response was 39.1 %. Before achieving hematologic and cardiac responses, mortality was 26.5 % and 29.9 %, respectively. The overall 5-year survival was 62.6 %, and the 5-year hematologic progression-free and major organ impairment-free survival was 39.3 %. Cox regression model confirmed 3 independent predictors of poor prognosis: the level of NT-proBNP ≥ 2500 pg/mL (p = 0.004), SVI < 25 mL/m2 (p = 0.0174), and prior syncope (p = 0.0191). The achievement of hematologic response had a positive effect on survival rates (p < 0.0001). CONCLUSION. A comprehensive assessment of cardiac damage by the time of primary AL amyloidosis diagnosis as well as appropriate treatment of this disease can reduce the risk of early cardiac mortality and enhance chances of not only achieving hematologic response but also improving survival rates.
- 1 July 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (3) , 237-245
Open AccessImpact of Cardiac Disease on Prognosis in Patients with Systemic AL Amyloidosis
AIM. To assess the clinical features as well as the factors affecting prognosis and long-term treatment outcomes in systemic AL amyloidosis patients with cardiac involvement. MATERIALS & METHODS. The trial enrolled 123 systemic AL amyloidosis patients with cardiac involvement who were treated at the RM Gorbacheva Scientific Research Institute in 2004–2023. The patients were 34–85 years of age (median 61 years); there were 61 women (49.6 %) and 62 men (50.4 %). RESULTS. Cardiac disease grades 1, 2, 3a, and 3b were identified in 13.8 %, 50.4 %, 17.9 %, and 17.9 % of AL amyloidosis patients, respectively. Chronic cardiac failure (CCF) developed in 65.9 % (n = 81), and severe cardiac failure was detected in 25.4 % (n = 31) of patients. Most of them (90,2 %), despite CCF, preserved left ventricular ejection fraction (> 40 %) with the mean value of 59.6 % (range 33–78 %). The left ventricular stroke volume index (SVI) was below the normal values (< 41 mL/m2) in 92.7 % of patients. The mean SVI value was 26.1 mL/m2 (range 8.3–49.5 mL/m2). The lower SVI was associated with cardiac disease grades. This parameter appeared to be 30.9 mL/m2, 26.8 mL/m2, 24.8 mL/m2, and 21.4 mL/m2 in grades 1, 2, 3a, and 3b (p = 0.006), respectively. Total global strain (TGS) in the left ventricle myocardium was decreased (< 20 %) in 94.6 % of patients. The mean TGS value was 13.8 % (range 4.4–34.8 %). TGS was diminishing with increasing cardiac disease grade (grade 1 with 17.8 %, grade 2 with 14.6 %, grade 3a with 13.1 %, and grade 3b with 9.6 %) (p = 0.007). Atrial fibrillation was reported in 23 % of patients, supraventricular tachycardia was observed in 31.9 %, and supraventricular extrasystoles were registered in 39.7 %. Ventricular extrasystoles were found in 73.7 % of patients, and ventricular tachycardia was seen in 13.2 %. Sinoatrial block was reported in 6.6 % of patients, and atrioventricular block was identified in 19.8 %. Syncope occurred in 12.3 % of patients. An artificial cardiac pacemaker was implanted in 8 patients. The thromboembolism rate was 13 %: the myocardial infarction rate was 11.4 %, and the rate of acute cerebrovascular accidents was 5.7 %. Atrial clots were detected in 2 (1.6 %) patients. The cumulative incidence of hematologic response for 2 years was 57 % and did not depend on cardiac disease grade, the 2-year rate of cardiac response was 39.1 %. Before achieving hematologic and cardiac responses, mortality was 26.5 % and 29.9 %, respectively. The overall 5-year survival was 62.6 %, and the 5-year hematologic progression-free and major organ impairment-free survival was 39.3 %. Cox regression model confirmed 3 independent predictors of poor prognosis: the level of NT-proBNP ≥ 2500 pg/mL (p = 0.004), SVI < 25 mL/m2 (p = 0.0174), and prior syncope (p = 0.0191). The achievement of hematologic response had a positive effect on survival rates (p < 0.0001). CONCLUSION. A comprehensive assessment of cardiac damage by the time of primary AL amyloidosis diagnosis as well as appropriate treatment of this disease can reduce the risk of early cardiac mortality and enhance chances of not only achieving hematologic response but also improving survival rates.